Latest evidence on COVID-19
Viral shedding, virus and substances of human origin (SoHO), role of asymptomatic and pre-symptomatic individuals and transmission risks in different settings
Incubation period, pathology and pathogenesis, viral shedding, and co-infections and secondary infections.
Diagnostic testing and screening
Diagnostic specimens, assay types, in-house tests versus in vitro diagnostic medical devices, intended use, rapidity and point of testing, diagnostic accuracy and validation, biosafety, testing capacity and methodologies
Immune responses and immunity
Immune responses (cell-mediated immune response and antibody-mediated immune response and protective immunity) and population immunity
Latest risk assessment
Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update
This risk assessment provides an overall update on the COVID-19 situation in the EU/EEA, including latest data on the situation with SARS-CoV-2 variants of concern covered by previous targeted risk assessments.
Risk assessment on COVID-19, 15 February 2021
ECDC risk assessments aim at supporting the EU/EEA countries and the European Commission in their preparedness and response to a public health threat.Read more